GleamWall
中文EN

ZNTL Zentalis Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1725160 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-33.8%
TTM net income YoY16.7%
TTM EPS YoY16.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-615.2%
Net margin-555.8%
FCF margin-498.8%
EBITDA margin-611.8%

Returns

ROE-49.2%
ROA-38.4%
ROIC (approx.)-49.6%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets22.7%
Debt / equity0.00x
Current ratio7.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0$0$26.86M
R&D expense$22.33M$35.16M$28.72M$29.49M$22.95M$27.61M$27.25M$32.97M
SG&A expense$8.82M$9.23M$9.14M$7.91M$10.78M$8.45M$10.58M$40.01M
Operating income-$31.15M-$44.39M-$37.85M-$37.39M-$33.73M-$36.06M-$45.62M-$49.85M
Pretax income-$28.70M-$42.15M-$35.23M-$34.77M-$26.69M-$26.87M-$48.28M-$47.68M
Income tax$118,000$138,000$120,000$442,000$0$0$0-$205,000
Net income-$28.82M-$42.29M-$35.35M-$35.22M-$26.69M-$26.87M-$48.28M-$47.47M
EBITDA-$31.00M-$44.24M-$37.70M-$37.24M-$33.57M-$35.90M-$45.36M-$49.53M
EPS (basic)-0.34-0.59-0.50—-0.37-0.37-0.67—
EPS (diluted)-0.34-0.59-0.50—-0.37-0.37-0.67—
Weighted avg. shares (diluted)84.61M71.33M70.26M—72.14M71.99M71.68M—
Balance sheet
Cash & equivalents$24.03M$24.78M$31.93M$35.99M$39.07M$37.60M$41.93M$36.53M
Short-term investments$204.86M$149.82M$179.83M$209.90M$239.22M$249.04M$278.37M$318.01M
Receivables———$0$0$0$0$5.00M
Current assets$237.27M$181.28M$218.10M$253.19M$288.30M$311.60M$342.88M$386.07M
PP&E, net$2.35M$2.50M$2.65M$2.77M$2.93M$3.09M$3.25M$4.70M
Goodwill———————$0
Total assets$270.19M$215.33M$253.07M$288.97M$327.25M$351.71M$384.02M$430.34M
Current liabilities$32.36M$37.63M$35.24M$36.56M$37.17M$39.02M$49.43M$52.73M
Total liabilities$65.31M$71.68M$70.39M$72.76M$74.38M$77.21M$88.64M$93.15M
Shareholders' equity$204.89M$143.65M$182.68M$216.20M$252.87M$274.50M$295.38M$337.19M
Shares outstanding98.26M71.67M71.16M69.09M72.25M72.14M71.95M71.28M
Cash flow statement
Operating cash flow-$32.71M-$37.24M-$32.96M-$30.94M-$26.96M-$34.71M-$32.64M-$39.70M
Capital expenditure$0$0$34,000$0$0$0$0$0
Free cash flow-$32.71M-$37.24M-$32.99M-$30.94M-$26.96M-$34.71M-$32.64M-$39.70M
Investing cash flow-$55.31M$30.02M$30.01M$32.45M$28.32M$30.38M$40.48M$32.28M
Financing cash flow$87.26M$65,000-$1.12M-$4.59M$115,000$0$189,000$0
Depreciation & amortization$152,000$152,000$151,000$157,000$160,000$160,000$262,000$317,000
Stock-based compensation$3.21M$3.21M$3.20M$3.12M$4.83M$6.29M$6.49M$31.36M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.